Preemptive Pharmacogenetic-Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery Pilot Trial

被引:1
|
作者
Staben, Rae [1 ]
Vnencak-Jones, Cindy L. [2 ]
Shi, Yaping [3 ]
Shotwell, Matthew S. [1 ,3 ]
Absi, Tarek [4 ]
Shah, Ashish S. [4 ]
Wanderer, Jonathan P. [1 ,5 ]
Beller, Marc [6 ]
Kertai, Miklos D. [1 ,7 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Cardiac Surg, Nashville, TN USA
[5] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA
[6] Vanderbilt Univ, Med Ctr, Ctr Precis Med, Nashville, TN USA
[7] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, 1211 21st Ave South,MAB 526, Nashville, TN 37212 USA
关键词
atrial fibrillation; cardiac surgery; beta-blockers; pharmacogenetic testing; CYP2D6; GENOTYPE; METABOLIZERS; ASSOCIATION; PHENOTYPE; RISK;
D O I
10.1053/j.jvca.2023.06.017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: To test the hypothesis that implementation of a cytochrome P-450 2D6 (CYP2D6) genotype guided perioperative metoprolol administration will reduce the risk of postoperative atrial fibrillation (AF), the authors conducted the Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery pilot study. Design: Clinical pilot trial. Setting: Single academic center. Participants: Seventy-three cardiac surgery patients. Measurements and Main Results: Patients were classified as normal, intermediate, poor, or ultrarapid metabolizers after testing for their CYP2D6 genotype. A clinical decision support tool in the electronic health record advised providers on CYP2D6 genotype guided metoprolol dosing. Using historical data, the Bayesian method was used to compare the incidence of postoperative AF in patients with altered metabolizer status to the reference incidence. A logistic regression analysis was performed to study the association between the metabolizer status and postoperative AF while controlling for the Multicenter Study of Perioperative Ischemia AF Risk Index. Of the 73 patients, 30% (n = 22) developed postoperative AF; 89% (n = 65) were normal metabolizers; 11% (n = 8) were poor/intermediate metabolizers; and there were no ultrarapid metabolizer patients identified. The estimated rate of postoperative AF in patients with altered metabolizer status was 30% (95% CI 8%-60%), compared with the historical reference incidence (27%). In the risk-adjusted analysis, there was insufficient evidence to conclude that modifying metoprolol dosing based on poor/intermediate metabolizer status was associated significantly with the odds of postoperative AF (odds ratio 0.82, 95% CI 0.15-4.55, p = 0.82). Conclusions: A CYP2D6 genotype guided metoprolol management was not associated with a reduction of postoperative AF after cardiac surgery. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:1974 / 1982
页数:9
相关论文
共 50 条
  • [21] Anticoagulation management of postoperative atrial fibrillation after cardiac surgery: A systematic review
    Yao, Ren Jie R.
    Hawkins, Nathaniel M.
    Lavaie, Yasaman
    Deyell, Marc W.
    Andrade, Jason G.
    Bashir, Jamil
    JOURNAL OF CARDIAC SURGERY, 2021, 36 (06) : 2081 - 2094
  • [22] Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: A cost/utility analysis using an analytic decision model
    Nshimyumukiza L.
    Duplantie J.
    Gagnon M.
    Douville X.
    Fournier D.
    Lindsay C.
    Parent M.
    Milot A.
    Giguère Y.
    Gagné C.
    Rousseau F.
    Reinharz D.
    Thrombosis Journal, 11 (1)
  • [23] Management of atrial fibrillation in the post-cardiac surgery setting
    Daoud, EG
    CARDIOLOGY CLINICS, 2004, 22 (01) : 159 - +
  • [24] IMPACT OF VASOPRESSORS ON POSTOPERATIVE ATRIAL FIBRILLATION IN CARDIAC SURGERY
    Kasper, Ashley Kate
    Wanek, Matthew
    Militello, Michael
    Hohlfelder, Benjamin
    Bauer, Seth
    Gillinov, A.
    Insler, Steven
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 397 - 397
  • [25] Risk factors for postoperative atrial fibrillation in cardiac surgery
    Rodriguez Rosales, Elizabeth
    de Arazoza Hernandez, Antonio
    Vazquez Castro, Francisco
    Moreno-Martinez, Francisco L.
    CORSALUD, 2014, 6 (02): : 174 - 180
  • [26] Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (the Postoperative Atrial Fibrillation in Cardiac Surgery Study [PACS2]
    Kim, MH
    Deeb, GM
    Morady, F
    Bruckman, D
    Hallock, LR
    Smith, KA
    Karavite, DJ
    Bolling, SF
    Pagani, FD
    Wahr, JA
    Sonnad, SS
    Kazanjian, PE
    Watts, C
    Williams, M
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (07): : 881 - 885
  • [27] Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview
    Bessissow, A.
    Khan, J.
    Devereaux, P. J.
    Alvarez-Garcia, J.
    Alonso-Coello, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S304 - S312
  • [28] Atrial fibrillation after cardiac surgery: Prevention and management: The Australasian experience
    Alawami, Mohammed
    Chatfield, Andrew
    Ghashi, Rajaie
    Walker, Laurence
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2018, 30 (01) : 40 - 46
  • [29] "Patient pathway"-guided management of atrial fibrillation: a pilot study
    Hasun, M.
    Kaltenbrunner, W.
    Ettl, B.
    Weidinger, F.
    Gatterer, E.
    WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 : S130 - S130
  • [30] Biochemical predictors of postoperative atrial fibrillation following cardiac surgery
    Sevket T. Turkkolu
    Emre Selçuk
    Cengiz Köksal
    BMC Cardiovascular Disorders, 21